TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02203786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1.
Study: NCT02256800
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: combined with 5-FU
Study: NCT02559960
Drug: Breviscapine Powder-Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
Study: NCT01681303
Drug: AST-120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02388568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Lifestyle Modification
Study: NCT01795339
Drug: AZD3293
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT01795339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT03156621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo SC Q2W
Study: NCT04598919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily by mouth for 24 weeks
Study: NCT00649571
Drug: Doxycycline Monohydrate Tablets (100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, single dose fasting
Study: NCT00649571
Drug: Adoxa Tablets 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, single dose fasting
Study: NCT00094666
Drug: Comparator: placebo / Duration of Treatment - 6 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00395512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets.
Study: NCT00483509
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
Study: NCT01570192
Drug: Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h
Approvals — FDA: no, EMA: no, PMDA: no
Description: a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
Study: NCT04573907
Drug: Drug Levothyroxine 100 mcg
Normalized name: levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of a 600 mcg levothyroxine dose
Study: NCT04573907
Drug: Drug Eutirox 100 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a 600 mcg levothyroxine dose
Study: NCT01091532
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: given orally twice daily for 14 days
Study: NCT01091532
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: given orally, once on Days 1 \& 14, and twice daily on Days 3-13.
Study: NCT02912520
Drug: Anti-Bacterial Agents
Normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of any antibiotic substance(s) over the course of 2 weeks
Study: NCT03073304
Drug: Crystalloid based prime solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid based prime solution
Study: NCT03073304
Drug: Erythrocyte based prime solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythrocyte based prime solution
Study: NCT00576238
Drug: urea
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application twice daily for up to 6 months
Study: NCT03561584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.
Study: NCT04576949
Drug: Cytisinicline
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablets containing 3 mg cytisinicline
Study: NCT04576949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablets containing matched placebo
Study: NCT03139253
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin 500 mg bid. for 14 days.
Study: NCT03139253
Drug: tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tetracycline 750 mg bid. for 14 days.
Study: NCT00624078
Drug: Antivenin Centruroides (scorpion) F(ab)2 Anascorp™
Approvals — FDA: no, EMA: no, PMDA: no
Description: three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
Study: NCT00003501
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00744445
Drug: r-HuEPO
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.
Study: NCT00366535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tabs b.i.d.
Study: NCT00366535
Drug: Neurotropin
Normalized name: neurotrophin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tabs b.i.d.
Study: NCT03383133
Drug: SULT Allosteric Inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
Study: NCT00725231
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
Study: NCT00194090
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02845596
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate
Study: NCT02845596
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide
Study: NCT02594878
Drug: Pamidronatdinatrium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04495478
Drug: Placebo - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT04495478
Drug: Placebo - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04210115
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04210115
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT03004131
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03765359
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets mimic metformin 500 mg tablets and insulin
Study: NCT02405637
Drug: simulated amniotic fluid 20cc/kg/day enterally
Approvals — FDA: no, EMA: no, PMDA: no
Description: simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
Study: NCT01013870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
Study: NCT00860431
Drug: AST-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6g/day (3 times a day)
Study: NCT00289978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients self-administered a fingolimod placebo capsule orally once daily.
Study: NCT04450901
Drug: YBL-006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of Administration: IV infusion; 0.5 mg/kg Q2W
Study: NCT04450901
Drug: YBL-006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of Administration: IV infusion; 2 mg/kg Q2W
Study: NCT04450901
Drug: YBL-006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of Administration: IV infusion; 5 mg/kg Q2W
Study: NCT04450901
Drug: YBL-006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of Administration: IV infusion; 10 mg/kg Q2W
Study: NCT04450901
Drug: YBL-006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration : IV infusion, 200 mg Q2W
Study: NCT04450901
Drug: YBL-006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration : IV infusion, 300 mg Q3W
Study: NCT04450901
Drug: YBL-006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration : IV infusion, 300 mg Q2W
Study: NCT04450901
Drug: YBL-006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration : IV infusion, 200mg Q2W
Study: NCT01137565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to AMG 853
Study: NCT01084759
Drug: Testosterone injection
Normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. \> 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
Study: NCT00004931
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00004931
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01122680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo inhalation solution
Study: NCT00501943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02374489
Drug: LDK378
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
Study: NCT00692237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 100 mg (3 capsules/day)
Study: NCT03779854
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03779854
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00000472
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00683319
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01584557
Drug: placebo or sugar pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill
Study: NCT00683319
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00737763
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
Study: NCT01189812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one time daily for 4 weeks
Study: NCT01229111
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01229111
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00442039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
Study: NCT04572841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous
Study: NCT02384343
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
Study: NCT03101670
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo oral tablet q.d.
Study: NCT00666575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
Study: NCT00063999
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03159442
Drug: AZD8871
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
Study: NCT03159442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for inhalation administered via single dose DPI
Study: NCT00147537
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 Arm A:~CP-751,871 20 mg/kg IV over 2.5 hours up to 17 cycles
Study: NCT00147537
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1b Dose Escalation/Expansion: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
Study: NCT00987935
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT00005596
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005596
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
Study: NCT00005596
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC \> 500/μL and platelets \> 75,000/uL
Study: NCT00005596
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.~IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22.
Study: NCT02533154
Drug: Prosicca
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prosicca eyedrops Dosage: on demand Route of administration: topical
Study: NCT00917020
Drug: Nasal CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-Needed during the 14 day Treatment Period
Study: NCT00917020
Drug: Inactive Placebo Gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02176525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02533154
Drug: Prosicca sine
Normalized name: tetrahydrozoline hydrochloride Ophthalmic Solution [Eye-Sine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosicca sine eyedrops Dosage: on demand Route of administration: topical
Study: NCT03760068
Drug: MYL-1601D Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: (100 U/mL)
Study: NCT03760068
Drug: FlexPen NovoLog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: (100 U/mL)
Study: NCT02631694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intake of placebo pill (40 milligram)
Study: NCT00163852
Drug: Normal saline IV, salt tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01512173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration twice daily
Study: NCT01871727
Drug: E7777 9 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
Study: NCT03844412
Drug: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).
Study: NCT03844412
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparison treatment will be an identical-appearing placebo Moisturel™ cream
Study: NCT03844412
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparison treatment will be an identical-appearing placebo pill
Study: NCT02294019
Drug: Ibuprofen 400 mg caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 milligram (mg) caplet according to Drug Facts label
Study: NCT03272165
Drug: MEDI1341
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
Study: NCT03272165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV infusion of placebo matched to MEDI1341.
Study: NCT02268305
Drug: MSM 1000mg twice a day (6000 mgs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
Study: NCT03535519
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard of care treatment with methotrexate
Study: NCT00214526
Drug: Conventional therapy with ICS+LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with ICS+LABA.
Study: NCT02009449
Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration on Day 1 and 2 of every 14 day cycle
Study: NCT02009449
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
Study: NCT01375985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous administration
Study: NCT03559257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT02514967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous injection once per week
Study: NCT04003389
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT02057666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
Study: NCT04469530
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A synthetic antineoplastic drug chemically related to the nitrogen mustards. The drug is administered orally daily, in the formulation appropriate for age.~The solution should be diluted in 20-30 ml of appropriate liquid before administration through nasogastric (NG) tube or gastrostomy (G) tube, with adequate flushing after administration to prevent obstruction of the feeding tube.
Study: NCT04469530
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug is administered orally daily, in the formulation appropriate for age.The solution is safe for administration through a nasogastric or G-tube.
Study: NCT02096965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive daily dose at 8 AM and at 4 PM.
Study: NCT01398475
Drug: LY3009104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04566380
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally twice daily
Study: NCT00507507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match FTC taken once daily
Study: NCT02194686
Drug: Dummy Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet twice per day for 12 weeks
Study: NCT00527878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no